Corvus Pharmaceuticals (CRVS) Shares Outstanding (2015 - 2026)

Corvus Pharmaceuticals' Shares Outstanding (Entity) history runs 12 years deep, the most recent figure standing at $84.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 23.35% year-over-year to $84.1 million; the TTM figure through Mar 2026 stood at $84.1 million (up 23.35% YoY), while the FY2025 annual figure was $74.7 million, up 10.01% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $84.1 million, up from $74.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $84.1 million in Q1 2026, with the low at $46.6 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $49.0 million (2023), against an average of $58.7 million.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) changed 0.0% in 2022, then jumped 39.01% in 2025.
• Corvus Pharmaceuticals' Shares Outstanding (Entity) stood at $46.6 million in 2022, then increased by 5.34% to $49.0 million in 2023, then soared by 38.46% to $67.9 million in 2024, then climbed by 10.01% to $74.7 million in 2025, then climbed by 12.58% to $84.1 million in 2026.
• Business Quant data shows CRVS's Shares Outstanding (Entity) at $84.1 million in Q1 2026, $74.7 million in Q4 2025, and $74.7 million in Q3 2025.